Clinical-stage biopharmaceutical company developing a bryostatin‑1 platform for Alzheimer’s and other neurodegenerative/cognitive diseases. Also pivoting to a digital-asset treasury strategy focused on acquiring and staking TAO cryptocurrency.
CEO: Joshua N. Silverman. Company website
TAO Synergies Inc. (TAOX) trades at $3.94, down 21.83% on the day, as of Sep 20, 2026 15:00 UTC.
TAO Synergies Inc. has a market capitalisation of $12.95M, calculated from the live TAOX share price and shares outstanding.
TAOX has no meaningful price-to-earnings ratio: TAO Synergies Inc. lost $12.70 per share over the last twelve months, and a P/E is only defined on positive earnings.
TAO Synergies Inc. generated revenue of $299,061.00 over the trailing twelve months, which puts the stock at 43.29 times sales.
TAOX has traded between $3.74 and $7.15 over the past 52 weeks, and the last price is 44.9% below that high.
No. TAO Synergies Inc. is loss-making, with a net margin of -9,609.23% over the trailing twelve months.
TAO Synergies Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Joshua N. Silverman is the chief executive of TAO Synergies Inc., which employs 4 people.
QFI Terminal shows TAOX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open TAOX in Terminal See plans